SOR102 Program
Oral anti-TNF⍺/anti-IL-23
Oral anti-TNF⍺/anti-IL-23
About the program
- SOR102 combines anti-TNF and anti-IL-23 Vorabodies into a single dual acting molecule
- A trypsin cleavable linker releases the monomers to independently engage their targets throughout intestinal tissue
- SOR102 provides combination therapy locally within inflamed tissue with minimal risk of systemic immunosuppression
Overall benefits of dual targeting approach:
- Increased efficacy through blockade of different inflammatory mechanisms of IBD
- No systemic immunosuppression or safety issues with oral dosing, facilitating long-term treatment and full neutralisation of both targets
- A single product for manufacture, formulation and development